Shaikhoo

Is Orchid Pharma Turnaround Candidate?

BSE:ORCHIDPHAR   None
Shaikhoology's Stock Analysis
#OrchidPhar - 474

Overview:-
Business got into trouble and filed insolvency which was taken over by Dhanuka Laboratories in 2020

MOAT- Company have few patented products (API)

Topline:-
YOY & QOQ improvement seen in recent results.

Profit Growth is Organic and Margin Expansion clearly visible

BottomLine :-
Debt reduction, Good Reserves and Positive Cash Flow shows Financial stability.


Valuations:-
Overvalued as of Now.
If Earning Growth Continues then valuations can be cheaper, needs EPS of 10-15 then stock price will attract new investors.


Technically - Chart is bullish at Cmp and their is hurdles also as trading in WDZ

Stock May See 1000-1200 levels(WSZ) if trades and sustains above 550 levels.

SHARED FOR EDUCATIONAL PURPOSE ONLY, I AM NOT SEBI REGISTERED ANALYST.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。